JUMPCAN(SH:600566) Shang Hai Zheng Quan Bao·2025-06-16 20:47Core Viewpoint - The announcement details Mr. Cao Fei's tender offer to acquire shares of Hubei Jichuan Pharmaceutical Co., Ltd., with a focus on the acquisition's timeline, purpose, and conditions [2][3][4]. Group 1: Tender Offer Details - The tender offer is valid from June 18, 2025, to July 17, 2025, with specific conditions regarding the withdrawal of acceptance in the last three trading days [2][6][9]. - Mr. Cao Fei intends to acquire 350,841,357 shares, representing 38.06% of the total share capital of the company, at a price of 26.93 yuan per share [5][6]. - The payment method for the tender offer will be in cash [4][5]. Group 2: Purpose of the Tender Offer - The tender offer is a result of a share transfer agreement between Mr. Cao Longxiang and Mr. Cao Fei, where 10.10% of Jiangsu Jichuan Holding Group Co., Ltd. was transferred to Mr. Cao Fei for 10.1 million yuan, indicating a family restructuring of shareholding [2][3]. - The acquisition aims to fulfill the legal obligation for a comprehensive tender offer, and it does not intend to terminate the listing status of Jichuan Pharmaceutical [3]. Group 3: Procedures for Acceptance - Shareholders can submit their acceptance of the tender offer through designated securities companies during the offer period, with specific codes for the tender offer [7][8]. - Accepted shares will be temporarily held by China Securities Depository and Clearing Corporation Limited during the offer period, and shareholders cannot transfer these shares until the withdrawal process is completed [8][10]. Group 4: Additional Information - The company will provide updates on the progress of the tender offer and will issue a results announcement after the offer period ends [6][13]. - Investors seeking detailed information can refer to the tender offer report published on June 16, 2025, on the Shanghai Stock Exchange website [15].